EC approves CROMA Pharma, Bausch + Lomb Yellox

Yellox is a non-steroidal anti-inflammatory drug (NSAID) indicated as a treatment for postoperative ocular inflammation following cataract extraction in adults.

Under an agreement signed between CROMA Pharma and Bausch + Lomb, both the companies will jointly promote the drug in Austria, France, Spain, Poland and Romania.

However, Bausch + Lomb will promote Yellox in the remaining EU member states.

Bausch + Lomb chief medical officer Cal Roberts said the drug helps meet the unmet needs of both patients and physicians alike across a number of European markets, offering them a new choice to treat post-operative ocular inflammation following cataract extraction.